We had introduced TMP kinase as a new hopeful antiprotozoal drug
target. We provided theoretical model for the eligibility of TMP kinase
from Plasmodium falciparum as a new drug target and we confirmed
our assumption by experimental trials based on mutational, catalytic
and molecular interference assays. Here we extended our new
antimicrobial model to include other blood protozoal infections as
anaplasmosis and babesiosis. Anaplamsa and babesia`s TMP kinase
shows important structural differences which can be targeted to
develop highly selective antiprotozoal drugs. Therefore, we estimate
that we are able to provide new broad spectrum antiprotozoal capable
of binding the more than one parasitic species. Furthermore, we
investigated the inhibitory activity of one new compound capable of
inhibiting the Plasmodium TMP kinase.